Cleared Traditional

K131513 - SCENAR (SCELAP, ENISAR, IPENS) CUTANEOUS ELECTRODE FAMILY

K131513 is an FDA 510(k) clearance for SCENAR (SCELAP, manufactured by Ritm Okb Zao. The device is a Class 2 Neurology device with product code GZJ cleared through the Traditional 510(k) pathway after a 409-day FDA review.

K131513 · Ritm Okb Zao · Neurology device
Download Printable Device Report (PDF) Official FDA 510(k) Summary (PDF)
Optimized for regulatory review, auditing and printing
Jul 2014
Decision
409d
Days
Class 2
Risk

K131513 is an FDA 510(k) clearance for the SCENAR (SCELAP, ENISAR, IPENS) CUTANEOUS ELECTRODE FAMILY. Classified as Stimulator, Nerve, Transcutaneous, For Pain Relief (product code GZJ), Class II - Special Controls.

Submitted by Ritm Okb Zao (Taganrog, RU). The FDA issued a Cleared decision on July 11, 2014 after a review of 409 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5890 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Neurology submissions.

FDA 510(k) Submission Details - K131513

510(k) Number K131513 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 28, 2013
Decision Date July 11, 2014
Days to Decision 409 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
260d slower than avg
Panel avg: 149d · This submission: 409d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GZJ Device Classification - Class 2, Special Controls

Product Code GZJ Stimulator, Nerve, Transcutaneous, For Pain Relief
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5890
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Peers - GZJ Stimulator, Nerve, Transcutaneous, For Pain Relief

All 451
Devices cleared under the same product code (GZJ) and FDA review panel - the closest regulatory comparables to K131513.
BiowaveHOME Neuromodulation Pain Therapy Device
K152437 · Biowave Corporation · Sep 2015
Synapse Transcutaneous Electrical Stimulation Device
K143198 · Synapse Electroceutical Limited · May 2015
Scrambler Therapy MC-5 A Device
K142666 · Delta International Services & Logistics S.R.L · May 2015
CP RELIEF WAND
K133779 · Mid-America Medical Innovations, LLC · May 2014
Best-AV2 Pro-Sport(tm)
K123099 · Avazzia, Inc. · May 2014
BODIHEALTH SYSTEM
K131675 · Eprt Technologies, Inc. · Mar 2014
K131513 · SCENAR (SCELAP, ENISAR, IPENS) CUTANEOUS ELECTRODE FAMILY
Download PDF FDA Summary Ritm Okb Zao